HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
5YBNGqrSvsjWejxt